Edgen Stock·Oct 30 2025, 20:15Back
Intellia Therapeutics Shares Decline Amid Clinical Hold on Nexiguran Ziclumeran Trials
Edgen Stock·Oct 30 2025, 20:15
[1] Intellia: Moving To 'Hold' Rating In Light Of Nex-Z Uncertainty In ATTR Patients (NTLA) | Seeking Alpha (https://seekingalpha.com/article/4835765-inte ...)[2] Intellia Therapeutics Halts Phase 3 CRISPR Trials After Patient Hospitalization with Severe Liver Injury - MedPath (https://vertexaisearch.cloud.google.com/groun ...)[3] Intellia drops after market close on FDA clinical hold on nex-z trials | Seeking Alpha (https://vertexaisearch.cloud.google.com/groun ...)
